Driving Advancement Through Scientific and Operational Innovation

Progress in biopharmaceutical science is happening at a pace that challenges even the most seasoned professionals to keep up. This issue of Pharmaceutical Technology® brings that momentum into sharp focus, offering readers a roadmap through scientific breakthroughs, operational innovation, and the cultural shifts required to deliver tomorrow’s medicines.

Our cover story, “Advancements in Biopharma Spur Industry-Wide Innovation,” looks at how messenger RNA platforms, cell and gene therapy pipelines, multispecific antibodies, and extracellular vesicle therapeutics are reshaping the commercial landscape. Thought leaders predict a future in which no single modality dominates; instead, diverse targeted options will coexist, forcing manufacturing and regulatory models to evolve quickly.

Building on that science, the Development feature, “Achieving Targeted Delivery with Nanoscale Systems,” details how lipid, polymeric, and biomimetic nanocarriers are boosting bioavailability and enabling combination therapies.

Downstream on the factory floor, our Manufacturing Q&A with ACG Packaging Materials’ Sheikh Akbar Ali, PhD, illustrates how digital printing techniques, solvent-free adhesives, and advancements in single-use packaging are helping manufacturers meet productivity goals and prioritize sustainability.

As always, quality and compliance remain front and center. Our Pharma Fundamentals feature, “ICH Q6B for Analytics” translates the quarter-century-old guideline into today’s high-resolution mass spectrometry workflows, clarifying expectations for primary sequence confirmation, glycan profiling, and disulfide mapping. Meanwhile, the Outsourcing feature delves into how artificial intelligence and “hybrid” contract and development organzanizations are redefining sponsor relationships amid geopolitical supply chain pressures.

This issue’s Ask the Expert series dives into the PDA/ANSI Standard 06-2025, offering practical advice for embedding leadership accountability, employee engagement, and technical excellence into an enterprise-wide quality culture.

Together, these articles underscore a central message: success in 2025 demands not only cutting-edge science, but agile operations and a values-driven culture that keeps quality at its core.

About the author

Mike Hennessy Jr is Chairman and CEO of MJH Life Sciences®.

Article details

Pharmaceutical Technology®
Volume 49, No. 5
June 2025
Page: 8

Citation

When referring to this article, please cite it as Hennessy, M. Driving Advancement Through Scientific and Operational Innovation. Pharmaceutical Technology 2025 49 (5).